XML 48 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
Assets and Liabilities Measured at Fair Value (Details)
$ in Thousands
 1 Months Ended 3 Months Ended
Jul. 05, 2016
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2016
item
Mar. 31, 2017
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Financial assets and liabilities subject to fair value measurements            
Transfer of assets from Level 1 to Level 2       $ 0    
Transfer of assets from Level 2 to Level 1       0    
Assets:            
Fair value of assets       236,884   $ 144,754
Liabilities:            
Contingent consideration payable       274,300   269,722
Derivative liability       101   265
Deferred compensation plan liability       1,847   1,479
Fair value of liabilities       276,248   271,466
Contingent consideration payable       274,300   269,722
Contingent consideration payable            
Balance, beginning of the period       269,722 $ 274,077  
Unrealized change in fair value change during the period, included in Statement of Operations       4,578 3,152  
Balance, end of the period       274,300 $ 277,229  
Foreign Currency Exchange Rate Exposure            
Number Of Forward Contracts | item     1      
Non-cash changes in the fair value of derivative liability       163    
Gain (loss) on derivative instruments       200    
Other current liabilities            
Foreign Currency Exchange Rate Exposure            
Derivative liabilities       100    
Scioderm            
Liabilities:            
Contingent consideration payable   $ 259,000   264,000    
Contingent consideration payable   $ 259,000   264,000    
MiaMed Inc            
Liabilities:            
Asset acquisition, potential aggregate deal value $ 89,500          
Clinical and Regulatory Approval milestones | Scioderm            
Liabilities:            
Contingent consideration payable       237,800    
Contingent consideration payable       237,800    
Revenue-based milestones | Scioderm            
Liabilities:            
Contingent consideration payable       26,200    
Contingent consideration payable       26,200    
Minimum | Clinical and Regulatory Approval milestones | Scioderm            
Liabilities:            
Discount rate (as a percent)   0.40%        
Minimum | Revenue-based milestones | Scioderm            
Liabilities:            
Discount rate (as a percent)   1.00%        
Maximum | Clinical and Regulatory Approval milestones | Scioderm            
Liabilities:            
Discount rate (as a percent)   1.10%        
Maximum | Revenue-based milestones | Scioderm            
Liabilities:            
Discount rate (as a percent)   2.20%        
Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc            
Liabilities:            
Contingent consideration payable upon achievement of milestones $ 83,000          
ATB200 Pompe program | Clinical and Regulatory Approval milestones | Callidus            
Liabilities:            
Contingent consideration payable       9,900    
Contingent consideration payable       9,900    
Commercial paper            
Assets:            
Fair value of assets       110,659   68,390
Corporate debt securities            
Assets:            
Fair value of assets       124,028   74,535
Money market            
Assets:            
Fair value of assets       2,197   1,829
Level 1            
Assets:            
Fair value of assets           144,754
Level 1 | Commercial paper            
Assets:            
Fair value of assets           68,390
Level 1 | Corporate debt securities            
Assets:            
Fair value of assets           74,535
Level 1 | Money market            
Assets:            
Fair value of assets           1,829
Level 2            
Assets:            
Fair value of assets       236,884    
Liabilities:            
Derivative liability       101   265
Deferred compensation plan liability       1,847   1,479
Fair value of liabilities       1,948   1,744
Level 2 | Commercial paper            
Assets:            
Fair value of assets       110,659    
Level 2 | Corporate debt securities            
Assets:            
Fair value of assets       124,028    
Level 2 | Money market            
Assets:            
Fair value of assets       2,197    
Level 3            
Liabilities:            
Contingent consideration payable       274,300   269,722
Fair value of liabilities       274,300   269,722
Contingent consideration payable       $ 274,300   $ 269,722
Level 3 | Revenue-based milestones | Monte Carlo | Scioderm            
Liabilities:            
Probability of achievement of milestones (as a percent)       66.50%    
Revenue volatility (as a percent)       51.00%    
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm            
Liabilities:            
Discount rate (as a percent)       0.80%    
Probability of achievement of milestones (as a percent)       66.50%    
Level 3 | Minimum | Revenue-based milestones | Monte Carlo | Scioderm            
Liabilities:            
Discount rate (as a percent)       1.40%    
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm            
Liabilities:            
Discount rate (as a percent)       1.30%    
Probability of achievement of milestones (as a percent)       100.00%    
Level 3 | Maximum | Revenue-based milestones | Monte Carlo | Scioderm            
Liabilities:            
Discount rate (as a percent)       2.70%    
Level 3 | ATB200 Pompe program | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus            
Liabilities:            
Discount rate (as a percent)       13.00%    
Level 3 | ATB200 Pompe program | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus            
Liabilities:            
Probability of achievement of milestones (as a percent)       32.00%    
Level 3 | ATB200 Pompe program | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus            
Liabilities:            
Probability of achievement of milestones (as a percent)       45.00%